CD4 and pneumocystosis: If it could be demonstrated from this evidence that individuals whose CD4 count is <200 cells/μL and VL are suppressed on antiretroviral therapy could discontinue prophylaxis with a risk of acquiring PCP similar to individuals in the other three groups, this finding would have important clinical implications and would indicate that a revision of clinical guidelines may be merited.